Tag Archives: Asterias Biotherapeutics

H.C. Wainwright Sticks to Their Buy Rating for Asterias Biotherapeutics

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST), with a price target of $11. The company’s shares closed on Friday at $2.50. According to TipRanks.com, Selvaraju is ranked 0

H.C. Wainwright Keeps a Buy Rating on Asterias Biotherapeutics

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today. The company’s shares closed yesterday at $2.55, close to its 52-week low of $2.00. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars

H.C. Wainwright Reaffirms Their Buy Rating on Asterias Biotherapeutics

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $12. The company’s shares closed yesterday at $3.40. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars

H.C. Wainwright Sticks to Its Buy Rating for Asterias Biotherapeutics

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $12. The company’s shares closed yesterday at $3.40. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars

H.C. Wainwright Keeps Their Buy Rating on Asterias Biotherapeutics

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $12. The company’s shares closed last Friday at $3.15. According to TipRanks.com, Selvaraju is ranked 0 out of 5

Asterias Biotherapeutics Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $12. The company’s shares closed last Friday at $3.20. Selvaraju observed: “We came away from this discussion with a